Therapixel

Clatz and Fillard, both researchers with PhDs in medical image analysis, leveraged their extensive academic and research backgrounds to establish the company. Their journey began at Inria, the French National Institute for Research in Digital Science and Technology, and Asclepios, a project-team focused on the analysis and simulation of biomedical images. This foundation in deep-tech and medical imaging research directly shaped Therapixel's trajectory.

Initially, the company focused on developing Fluid, a touchless image navigation software for operating rooms. This system allowed surgeons to access and manipulate medical images using gesture control, thereby maintaining a sterile environment. However, a significant pivot occurred after the company's algorithm won the global Digital Mammography DREAM Challenge in 2017. This achievement, which benchmarked their AI against 1,200 others in identifying cancerous lesions in mammograms, redirected the company's focus towards breast cancer screening.

The company's core product is MammoScreen®, an AI-powered software designed to assist radiologists in interpreting mammograms. The software analyzes mammograms and assigns a suspicion score, ranging from 1 to 10, to indicate the probability of malignancy for each finding. This tool aims to improve the accuracy and efficiency of breast cancer detection, helping to reduce the number of false negatives and alleviate the workload of radiologists. MammoScreen integrates with existing Picture Archiving and Communication Systems (PACS) used by healthcare providers.

Therapixel's business model is centered on selling its software solution to hospitals, clinics, and imaging centers. The company has secured regulatory approvals, including CE marking in Europe and FDA clearance in the United States, allowing it to commercialize its product in these key markets. Its client base consists of healthcare providers specializing in radiology and breast imaging.